Stoke Therapeutics Doses The First Patient In Phase 1 OSPREY Study Of STK-002 For Autosomal Dominant Optic Atrophy

Stoke Therapeutics -0.56%

Stoke Therapeutics

STOK

35.34

-0.56%

  • Dose-escalating study will evaluate the safety, tolerability and exposure of STK-002 in people with ADOA.
  • Changes in visual function, ocular structure and quality of life to be evaluated as secondary objectives.
  • ADOA is the most common inherited optic nerve disorder and is primarily caused by variants in the OPA1 gene that result in progressive and irreversible vision loss
This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.